课题基金 / 基金详情

Innovative Immunotherapy Approach in Chimeric Antigen Receptor based therapy for acute leukemia using transplantation of genetically modified hematopoietic stem cells.

Innovative Immunotherapy Approach in Chimeric Antigen Receptor based therapy for acute leukemia using transplantation of genetically modified hematopoietic stem cells.
使用转基因造血干细胞移植治疗急性白血病的嵌合抗原受体创新免疫治疗方法。
批准号:
406459
负责人:
Dasari Harika
金额:
$1.27万
依托单位:
依托单位国家:
加拿大
项目类别:
Studentship Programs
财政年份:
2018
资助国家:
加拿大
项目状态:
已结题
起止时间:
2018-12-01 至 2019-12-01

项目摘要

项目成果

Dasari Harika的其他基金

相似基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
Acute lymphoblastic leukemia is the most common pediatric cancer and, despite an 80% remission rate, it remains the most lethal pediatric cancer. A promising new therapeutic tool for resistant leukemias uses engineered T cells to express a chimeric antige
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Chimeric antigen receptors on regulatory T cells as a treatment strategy in auto-immune diseases.
海外基金